ChromaDex Corporation

1.86-0.0600-3.12%Vol 646.00K1Y Perf -79.04%
Jun 27th, 2022 16:00 DELAYED
BID1.84 ASK1.94
Open1.98 Previous Close1.92
Pre-Market- After-Market-
 - -  - -%
Target Price
6.87 
Analyst Rating
Strong Buy 1.00
Potential %
269.36 
Finscreener Ranking
★★★★     52.99
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★+     43.64
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
★★     47.10
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.78 
Earnings Rating
Strong Sell
Market Cap127.10M 
Earnings Date
2nd Aug 2022
Alpha0.00 Standard Deviation0.31
Beta1.78 

Today's Price Range

1.801.98

52W Range

1.5110.78

5 Year PE Ratio Range

-27.50-8.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
17.07%
1 Month
12.94%
3 Months
-18.99%
6 Months
-53.51%
1 Year
-79.04%
3 Years
-49.21%
5 Years
-46.96%
10 Years
-2.88%

TickerPriceChg.Chg.%
CDXC1.86-0.0600-3.12
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Financial StrengthValueIndustryS&P 500US Markets
1.40
2.40
0.13
0.18
-623.70
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
61.10
-39.20
-36.70
-63.30
-39.25
RevenueValueIndustryS&P 500US Markets
70.03M
1.02
21.73
26.22
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.09-0.11-22.22
Q04 2021-0.11-0.0827.27
Q03 2021-0.10-0.13-30.00
Q02 2021-0.09-0.0811.11
Q01 2021-0.09-0.12-33.33
Q04 2020-0.11-0.109.09
Q03 2020-0.11-0.0736.36
Q02 2020-0.11-0.0645.45
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.08-14.29Negative
9/2022 QR-0.08-60.00Negative
12/2022 FY-0.32-33.33Negative
12/2023 FY-0.150.00-
Next Report Date2nd Aug 2022
Estimated EPS Next Report-0.08
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume646.00K
Shares Outstanding68.33K
Shares Float60.22M
Trades Count4.38K
Dollar Volume1.20M
Avg. Volume1.09M
Avg. Weekly Volume1.92M
Avg. Monthly Volume769.30K
Avg. Quarterly Volume595.41K

ChromaDex Corporation (NASDAQ: CDXC) stock closed at 1.92 per share at the end of the most recent trading day (a -9% change compared to the prior day closing price) with a volume of 5.35M shares and market capitalization of 127.10M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. ChromaDex Corporation CEO is Robert N. Fried.

The one-year performance of ChromaDex Corporation stock is -79.04%, while year-to-date (YTD) performance is -48.66%. CDXC stock has a five-year performance of -46.96%. Its 52-week range is between 1.51 and 10.78, which gives CDXC stock a 52-week price range ratio of 3.78%

ChromaDex Corporation currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 4.33, a price-to-sale (PS) ratio of 1.60, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.09%, a ROC of -72.49% and a ROE of -78.86%. The company’s profit margin is -39.25%, its EBITDA margin is -36.70%, and its revenue ttm is $70.03 Million , which makes it $1.02 revenue per share.

Of the last four earnings reports from ChromaDex Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. ChromaDex Corporation’s next earnings report date is 02nd Aug 2022.

The consensus rating of Wall Street analysts for ChromaDex Corporation is Strong Buy (1), with a target price of $6.87, which is +269.36% compared to the current price. The earnings rating for ChromaDex Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ChromaDex Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ChromaDex Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 46.69, ATR14 : 0.21, CCI20 : 41.54, Chaikin Money Flow : -0.26, MACD : 0.00, Money Flow Index : 34.10, ROC : -10.28, RSI : 50.57, STOCH (14,3) : 41.56, STOCH RSI : 0.60, UO : 45.32, Williams %R : -58.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ChromaDex Corporation in the last 12-months were: Robert N. Fried (Buy at a value of $54 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ChromaDex Corporation

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN nicotinamide riboside, sold directly to consumers as TRU NIAGEN, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN is helping the world AGE BETTER. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

CEO: Robert N. Fried

Telephone: +949.419.0288 ext. 127

Address: 10900 Wilshire Boulevard, Los Angeles 90024, CA, US

Number of employees: 110

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

63%38%

Bearish Bullish

57%43%

TipRanks News for CDXC

Mon, 18 Apr 2022 10:25 GMT Chromadex (CDXC) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits